Mutation in ERBB2 Linked to Liver Cancer
Author Information
Author(s): Tanios Bekaii-Saab, Nita Williams, Christoph Plass, Miguel Villalona Calero, Charis Eng
Primary Institution: The Ohio State University
Hypothesis
Are there gain-of-function mutations in EGFR and ERBB2 in hepatoma and biliary cancers?
Conclusion
11% of hepatoma samples had a novel ERBB2 mutation, which may help predict response to targeted therapy.
Supporting Evidence
- 11% of hepatoma samples had the ERBB2 mutation.
- No biliary cancer samples had the ERBB2 mutation.
- The study suggests a low yield of EGFR mutations in hepatoma.
Takeaway
Some liver cancer samples have a special change in a gene that might help doctors choose better treatments.
Methodology
Genomic DNA was extracted from 40 hepatoma and biliary cancer samples and sequenced to detect mutations.
Limitations
The study's findings may not apply to all hepatobiliary cancers due to the small sample size.
Participant Demographics
18 hepatoma and 22 biliary cancer samples were analyzed.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website